These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 7143218)

  • 41. Effect of food on bioavailability of nalidixic acid from uncoated tablets having different dissolution rates.
    Ogata H; Aoyagi N; Kaniwa N; Ejima A
    J Pharmacobiodyn; 1984 Oct; 7(10):760-7. PubMed ID: 6520698
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Plasma concentrations, bioavailability and dissolution of chlorpropamide.
    Taylor T; Assinder DF; Chasseaud LF; Bradford PM; Burton JS
    Eur J Clin Pharmacol; 1977 Mar; 11(3):207-212. PubMed ID: 15845
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study.
    Fujioka Y; Kadono K; Fujie Y; Metsugi Y; Ogawara K; Higaki K; Kimura T
    J Control Release; 2007 Jun; 119(2):222-8. PubMed ID: 17442444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats.
    Dahan A; Hoffman A
    Eur J Pharm Biopharm; 2007 Aug; 67(1):96-105. PubMed ID: 17329087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Species differences in the dissolution and absorption of griseofulvin and albendazole, biopharmaceutics classification system class II drugs, in the gastrointestinal tract.
    Tanaka Y; Waki R; Nagata S
    Drug Metab Pharmacokinet; 2013; 28(6):485-90. PubMed ID: 23629744
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Formulation-dependent stability mechanisms affecting dissolution performance of directly compressed griseofulvin tablets.
    Maclean N; Khadra I; Mann J; Abbott A; Mead H; Markl D
    Int J Pharm; 2023 Jan; 631():122473. PubMed ID: 36493970
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bioavailability of digoxin in a new soluble pharmaceutical formulation in capsules.
    Ghirardi P; Catenazzo G; Mantero O; Merotti GC; Marzo A
    J Pharm Sci; 1977 Feb; 66(2):267-9. PubMed ID: 839426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evaluating bioequivalence of meloxicam tablets: is in-vitro dissolution test overdiscriminating?
    Jin C; Zhao C; Shen D; Dong W; Liu H; He Z
    J Pharm Pharmacol; 2018 Feb; 70(2):250-258. PubMed ID: 29193077
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of formulation on dissolution and bioavailability of phenytoin tablets.
    Chakrabarti S; Belpaire F; Moerman E
    Pharmazie; 1980; 35(10):627-9. PubMed ID: 7454745
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results.
    Welling PG; Patel RB; Patel UR; Gillespie WR; Craig WA; Albert KS
    J Pharm Sci; 1982 Nov; 71(11):1259-63. PubMed ID: 7175719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bioavailability of hydrocortisone from commercial 20-mg tablets.
    Patel RB; Rogge MC; Selen A; Goehl TJ; Shah VP; Prasad VK; Welling PG
    J Pharm Sci; 1984 Jul; 73(7):964-6. PubMed ID: 6470962
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancement of bioavailability of griseofulvin by its complexation with beta-cyclodextrin.
    Dhanaraju MD; Kumaran KS; Baskaran T; Moorthy MS
    Drug Dev Ind Pharm; 1998 Jun; 24(6):583-7. PubMed ID: 9876628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo evaluation of two new sustained release formulations elaborated by one-step melt granulation: level A in vitro-in vivo correlation.
    Ochoa L; Igartua M; Hernández RM; Solinís MA; Gascón AR; Pedraz JL
    Eur J Pharm Biopharm; 2010 Jun; 75(2):232-7. PubMed ID: 20159037
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Power of test in bioequivalence analysis. The comparison of tests in beagle dogs and humans].
    Kaniwa N; Ogata H; Aoyagi N; Ejima A; Sakuma A
    Yakugaku Zasshi; 1984 Feb; 104(2):175-83. PubMed ID: 6737228
    [No Abstract]   [Full Text] [Related]  

  • 55. Influence of high fat diet on GI absorption of griseofulvin tablets in man.
    Khalafalla N; Elgholmy ZA; Khalil SA
    Pharmazie; 1981 Oct; 36(10):692-3. PubMed ID: 7312923
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
    Liu C; Chen Z; Chen Y; Lu J; Li Y; Wang S; Wu G; Qian F
    Mol Pharm; 2016 Feb; 13(2):599-608. PubMed ID: 26709621
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fast-dissolving microparticles fail to show improved oral bioavailability.
    Wong SM; Kellaway IW; Murdan S
    J Pharm Pharmacol; 2006 Oct; 58(10):1319-26. PubMed ID: 17034654
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Studies on formulation and bioavailability of benorilate tablets].
    Chen J; Tu XD
    Yao Xue Xue Bao; 1994; 29(9):707-12. PubMed ID: 7900541
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Correlations between in vitro dissolution rate and bioavailability of alaproclate tablets.
    Graffner C; Nicklasson M; Lindgren JE
    J Pharmacokinet Biopharm; 1984 Aug; 12(4):367-80. PubMed ID: 6527230
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cinnarizine food-effects in beagle dogs can be avoided by administration in a Self Nano Emulsifying Drug Delivery System (SNEDDS).
    Christiansen ML; Holm R; Kristensen J; Kreilgaard M; Jacobsen J; Abrahamsson B; Müllertz A
    Eur J Pharm Sci; 2014 Jun; 57():164-72. PubMed ID: 24239996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.